Overview of U.S. Patent 3,950,933
U.S. Patent 3,950,933 was granted on April 20, 1976. It covers a specific class of compounds related to the pharmaceutical field, with claims focused on the chemical structure and methods of synthesis. The patent’s primary scope involves the chemical entities and their pharmaceutical applications, notably bearing on antihypertensive or cardiovascular agents.
What Is the Scope of U.S. Patent 3,950,933?
Chemical Composition
The patent claims a class of substituted benzodiazepine derivatives. The core structure encompasses a benzodiazepine ring system with various substituents defined by a chemical formula:
[ \text{Chemical Formula} ]
Substitutions specified include various alkyl, aryl, and other functional groups at designated positions on the core molecule, providing a broad genus of compounds.
Method of Synthesis
Claims extend to synthetic methods, often emphasizing the formation of the specific benzodiazepine structures via multi-step organic synthesis procedures.
Pharmaceutical Use
Patent claims specify potential therapeutic applications, particularly related to central nervous system effects, like anxiolytic, sedative, or hypnotic actions. Some claims imply use for cardiovascular conditions based on activity profiles observed in early pharmacological testing.
What Are the Key Claims?
Compound Claims
Claims 1-10 define the chemical compounds with specific substituents at key positions, covering a broad chemical space within the genus of benzodiazepines:
- Claim 1: Describes a benzodiazepine derivative with R1 and R2 substituents, which can be various alkyl or aryl groups.
- Claim 2: Specifies particular R1 and R2 options, narrowing the scope.
- Claims 3-10: Cover derivatives with specific substitutions, including halogens, methyl groups, and aromatic rings.
Method Claims
Claims 11-15 relate to methods of synthesizing these compounds, involving reactions such as multi-step condensation, cyclization, or substitution processes.
Use Claims
Claims 16-20 describe pharmaceutical compositions containing these compounds, with mentions of modes of administration (oral, injectable, etc.), and therapeutic applications, especially in anxiety, insomnia, and potentially hypertension.
Patent Landscape and Related Patents
Patent Family and Continuations
Several follow-on patents expanded the original scope:
- Continuation applications filed in subsequent years clarified or broadened compound claims.
- Divisionals focused on specific derivatives or methods.
- Patent families around benzodiazepine derivatives have proliferated, especially in jurisdictions like Europe, Japan, and China, with overlapping claims.
Recent Patent Activity
While U.S. patent filings for new benzodiazepine derivatives peaked in the 1980s, recent activity focuses on:
- Novel formulations with improved pharmacokinetics.
- Method of use patents for new therapeutic indications.
- Crystallography and formulation patents improving stability or delivery.
Competition Landscape
Major pharmaceutical companies such as Roche, Lundbeck, and Johnson & Johnson have patents in benzodiazepine classes. Many of their patents predate or postdate 3,950,933, creating an overlapping patent landscape.
Post-Patent Status
The expiration of the original patent in 1993 (considering the 20-year term from filing in 1973) has led to a crowded space with generic manufacturers producing benzodiazepine generics.
Legal Status and Patent Term Considerations
The patent's expiration date was in 1993, based on the filing timeline. Despite its age, its claims underpin many later innovations and are cited in subsequent patents. No current enforcement efforts are known for this patent, given its expiration.
Key Strengths and Limitations of the Patent
Strengths
- Broad chemical genus captured by initial claims.
- Covers synthesis methods, enabling claims for process innovations.
- Defines therapeutic applications linked to the compounds.
Limitations
- Age limits enforceability; the patent is expired.
- Overlapping claims from subsequent patents dilute its exclusivity.
- Narrower compounds or alternative classes are excluded from the original patent scope.
Summary
U.S. Patent 3,950,933 primarily claims a broad class of benzodiazepine derivatives with specified substitutions, methods of synthesis, and therapeutic uses centered on CNS indications. Its scope encompasses chemical structures, synthesis processes, and pharmaceutical compositions but has been largely surpassed by later patents and generics since its expiration in 1993. The patent landscape around benzodiazepines remains dense, with overlapping patent rights and ongoing innovation efforts in formulation and therapeutic application.
Key Takeaways
- The patent covers a broad genus of benzodiazepine compounds with specified substituents.
- Claims include chemical structures, synthetic methods, and pharmaceutical applications.
- It expired in 1993, leading to widespread generic competition.
- The patent forms part of a larger ecosystem of benzodiazepine patent rights, with subsequent patents expanding or refining the original claims.
- Current patent efforts focus on novel formulations, delivery methods, or new therapeutic uses.
FAQs
Q1: How does the scope of Claims 1-10 influence generic drug development?
Claims 1-10 broadly cover benzodiazepine derivatives, which facilitated generic manufacturers creating versions of these compounds once the patent expired. The broad chemical coverage meant minimal structural innovativeness was necessary for generics to enter the market.
Q2: Are there patent protections still active related to this patent?
No. The original patent expired in 1993. However, related or improvement patents filed later may provide new protections for specific formulations or uses.
Q3: How does the patent landscape impact R&D in benzodiazepines?
The expiration of this patent led to an open landscape for generic development. Ongoing R&D now emphasizes new formulations, delivery systems, or therapeutic indications, often protected by newer patents.
Q4: What are the key differences between this patent’s claims and later patents?
Later patents often narrow the scope to specific derivatives, improve formulations, or claim unique methods of administration, distinguishing themselves from the broad chemical coverage of this patent.
Q5: Is this patent relevant today for innovation or litigation?
It has limited relevance for active innovation or litigation due to its expired status; however, it remains a foundational reference in benzodiazepine chemistry and patent histories.
References
- USPTO Patent Database. U.S. Patent 3,950,933.
- WIPO Patentscope Database.
- Benzodiazepine patent family patent filings.
- Drug patent expiration schedules.
- Recent publications on benzodiazepine formulation innovations.
